

2.1 Publications mentioned in the Pubmed server and Sigaps software

SIGAPS: The calculation method is based on the author's place in the publication and the valuation of the journal.

Remember that a publication is counted (MERRI revenues) for CJP only if at least one author is an employee of the Centre and if the publication is mentioned by the SIGAPS software (the rules can however evolve from one year to the next).

1. N KENTISH-BARNES S CHEVRET, S VALADE, S JABER, L KERHUEL, O GUISSET, M MARTIN, A MAZAUD, LAURENT PAPA ZIAN, L ARGAUD, A DEMOULE, D SCHNELL, E LEBAS, F ETHUIN, E HAMMAD, S MERCERON, J AUDIBERT, C B, P-Y DELANNOY, **A LAUTRETTE**, O LESIEUR, A RENAULT, D REUTER, N TI, B PHILIPPON-JOUE, M FIANCETTE, M RAMAKERS, J-P RIGAUD, V SOUPPART, K ASEHNOUNE, B CHAMPIGNEULLE, D GOLDGRAN-TOLEDANO, J-L DUBOST, P-E BOLLAERT, R CHOUQUER, F POCHARD, A CARIOU, E AZOULAY A three-step support strategy for relatives of patients dying in the intensive care unit: a cluster randomised trial Randomized Controlled Trial. 2022 Feb 12 ;399(10325) :656-664 I.F : 202.731 Sigaps : A+ k

2. S LEBOULLEUX, C BOURNAUD, C N CHOUGNET, S ZERDOUD, A AL GHUZLAN¹, B CATARGI, C DO CAO, **A KELLY**, M-L BARGE, L LACROIX, I DYGAJ, P VERA, D RUSU, O SCHNEEGANS, D BENISVY, M KLEIN, J ROUX, M-C EBERLE, D BASTIE, C NASCIMENTO, A-L GIRAUDET, N LE MOULLEC, S BARDET, D DRUI, N ROUDAUT, Y GODBERT, O MOREL, A DRUTEL, L LAMARTINA, C SCHVARTZ, F-L VELAYOUDOM, M-J SCHLUMBERGER, L LEENHARDT, I BORGET Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer N Engl J Med. 2022 Mar 10 ;386(10) :923-932 I.F : 176.079 Sigaps : A+ k

3. P SCHMID, J CORTES, R DENT, L PUSZTAI, H MCARTHUR, S KÜMMEL, J BERGH, C DENKERT, Y HEE PARK, R HUI, N HARBECK, M TAKAHASHI, M UNTCH, P A FASCHING, F CARDOSO, J ANDERSEN, D PATT, M DANSO, M FERREIRA, **M-A MOURET-REYNIER**, S- IM, J-H AHN, M GION, S BARON-HAY, J-F BOILEAU, Y DING, K TRYFONIDIS, G AKTAN, V KARANTZA, J O'SHAUGHNESSY, KEYNOTE-522 Investigators Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer N Engl J Med. 2022 Feb 10 ;386(6) :556-567 I.F : 176.079 Sigaps : A+ k

4. A W THILLE, A GACOUIN, R COUDROY, S EHRMANN, J-P QUENOT, M-A NAY, C GUITTON, D CONTOU, G LABRO, J REIGNIER, G PRADEL, G BEDUNEAU, L DANGERS, C SACCHERI, G PRAT, G LACAVE, N SEDILLOT, N TERZI, B LA COMBE, J-P MIRA, A ROMEN, M-A AZAIS, A ROUZE, J DEVAQUET, A DELBOVE, M DRES, J BOURENNE, **A LAUTRETTE**, J DE KEIZER, S RAGOT, J-P FRAT; REVA RESEARCH NETWORK Spontaneous-Breathing Trials with Pressure-Support Ventilation or a T-Piece N Engl J Med. 2022 Nov 17 ;387(20) :1843-1854 I.F : 176.079 Sigaps : A+ k

5. F ANDRE, T FILLERON, M KAMAL, F MOSELE, M ARNEDOS, F DALENC, M-P SABLIN, M CAMPONE, H BONNEFOI, C LEFEUVRE-PLESSE, W JACOT, F COUSSY, J-M FERRERO, G EMILE, **M-A MOURET-REYNIER**, J-C THERY, N ISAMBERT, A MEGE, P BARTHELEMY, B YOU, N HAJAJI, L LACROIX, E ROULEAU, A TRAN-DIEN, S BOYAULT, V ATTIGNON, P GESTRAUD, N SERVANT, C LE TOURNEAU, L LARBI CHERIF, I SOUBEYRAN, F MONTEMURRO, A MOREL, A LUSQUE, M JIMENEZ, A JACQUET, A GONÇALVES, T BACHELOT, I BIECHE Genomics to select treatment for patients with metastatic breast cancer Nature. 2022 Oct ;610(7931) :343-348 I.F : 69.504 Sigaps : A+ k

- 6.** F-C BIDARD, A-C HARDY-BESSARD, F DALENC, T BACHELOT, J-Y PIERGA, T DE LA MOTTE ROUGE, R SABATIER, C DUBOT, J-S FRENEL, J M FERRERO, S LADOIRE, C LEVY, **M-A MOURET-REYNIER**, A LORTHOLARY, J GRENIER, C CHAKIBA, L STEFANI, J EDOUARD PLAZA, F CLATOT, L TEIXEIRA, V D'HONDT, H VEGAS, ODERBEL, C GARNIER-TIXIDRE, J-L CANON, B PISTILLI, F ANDRE, L ARNOULD, A PRADINES, I BIECHE, C CALLENS, J LEMONNIER, F BERGER, S DELALOGUE, PADA-1 INVESTIGATORS Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial *Lancet Oncol.* 2022 Nov ;23(11) :1367-1377 I.F : 54.433 Sigaps : A k
- 7.** T BACHELOT, P COTTU, S CHABAUD, F DALENC, D ALLOUACHE, S DELALOGUE, J-P JACQUIN, J GRENIER, L VENAT BOUVET, A JEGANNATHEN, M CAMPONE, F DEL PIANO, M DEBLED, A-C HARDY-BESSARD, S GIACCHETTI, **M-A MOURET-REYNIER**, P BARTHELEMY, L KALUZINSKI, A MAILLIEZ, E LEGOUFFE, M SEPHTON, J BLISS, J-L CANON, F PENAULT-LLORCA, J LEMONNIER, D CAMERON, F ANDRE Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. *J Clin Oncol.* 2022 Nov 10 ;40(32) :3699-3708 I.F : 50.717 Sigaps : A k
- 8.** F-C BIDARD, V G KAKLAMANI, P NEVEN, G STREICH, A J MONTERO, F FORGET, **M-A MOURET-REYNIER**, J HYUK SOHN, D TAYLOR, K K HARNDEN, H KHONG, J KOCSIS, F DALENC, P M DILLON, S BABU, S WATERS, I DELEU, J A GARCIA SAENZ, E BRIA, M CAZZANIGA, J LU, P AFTIMOS, J CORTES, S LIU, G TONINI, D LAURENT, N HABBOUBI, M G CONLAN, A BARDIA Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. *J Clin Oncol.* 2022 Oct 1 ;40(28) :3246-3256 I.F : 50.717 Sigaps : A k
- 9.** C PFISTER, G GRAVIS, A FLECHON, C CHEVREAU, **H MAHAMMEDI**, B LAGUERRE, A GUILLOT, F JOLY, M SOULIE, Y ALLORY, V HARTE, S CULINE, VESPER TRIAL INVESTIGATORS Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial *J Clin Oncol.* 2022 Jun 20 ;40(18) :2013-2022 I.F : 50.171 Sigaps : A k
- 10.** A W THILLE, R COUDROY, M-A NAY, A GACOUIN, M DECAVELE, R SONNEVILLE, F BELONCLE, C GIRAULT, L DANGERS, **A LAUTRETTE**, Q LEVRAT, A ROUZE, E VIVIER, J-B LASCARROU, J-D RICARD, A MEKONTSO-DESSAP, G BARBERET, C LEBERT, S EHRMANN, A MASSRI, J BOURENNE, G PRADEL, P BAILLY, N TERZI, J DELLAMONICA, G LACAVE, R ROBERT, J-P FRAT, S RAGOT; HIGH-WEAN STUDY GROUP AND THE REVA RESEARCH NETWORK Beneficial Effects of Noninvasive Ventilation after Extubation in Obese or Overweight Patients: A Post Hoc Analysis of a Randomized Clinical Trial *Am J Respir Crit Care Med.* 2022 Feb 15 ;205(4) :440-449 I.F : 30.528 Sigaps : A k
- 11.** Y LORIOT, M TEXIER, S CULINE, A FLECHON, A THIERY-VUILLEMIN, G GRAVIS, L GEOFFROIS, C CHEVREAU, M GROSS-GOUPIL, P BARTHELEMY, E BOMPAS, **H MAHAMMEDI**, B LAGUERRE, S ABADIE LACOURTOISIE, C HELISSEY, S LADOIRE, C ABRAHAM, C MASSARD, S GRIMALDI, K FIZAZI The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography *Eur Urol.* 2022 Aug ;88(2) : 172-179 I.F : 24.267 Sigaps : A k

12. F THOUY, J BOHE, B SOUWEINE, H ABIDI, J-P QUENOT, F THIOILLIERE, J DELLAMONICA, J-C PREISER, J-F TIMSIT, V BRUNOT, A KLICH, N SEDILLOT, X TCHENIO, J-B ROUDAUT, N MOTTARD, H HYVERNAT, F WALLET, P-E DANIN, J BADIE, R JOSPE, J MOREL, A MOFREDJ, A FATAH, J DRAI, A MIALON, A AIT HSSAIN, **A LAUTRETTE**, E FONTAINE, C-H VACHERON, D MAUCORT-BOULCH, K KLOUCHE, C DUPUIS Impact of prolonged requirement for insulin on 90-day mortality in critically ill patients without previous diabetic treatments: a post hoc analysis of the CONTROLLING randomized control trial Crit Care. 2022 May 16 ;26(1) :138 I.F : 19.334 Sigaps : A k

13. N PENEL, S BONVALOT, A-M BIMBAI, A MEURGEY, F LE LOARER, S SALAS, S PIPERNO-NEUMANN, C CHEVREAU, P BOUDOU-ROUQUETTE, **P DUBRAY-LONGERAS**, J-E KURTZ, C GUILLEMET, E BOMPAS, A ITALIANO, A LE CESNE, D ORBACH, J THERY, M-C LE DELEY, J-Y BLAY, O MIR Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis Clin Cancer Res. 2022 Sep 15 ;28(18) :4105-4111 I.F : 13.801 Sigaps : A K

14. O DE CALBIAC, A LUSQUE, A MAILLIEZ, T BACHELOT, L UWER, **M-A MOURET-REYNIER**, G EMILE, C JOUANNAUD, A GONÇALVES, A PATSOURIS, V DIERAS, M LEHEURTEUR, T PETIT, P COTTU, J-M FERRERO, V D'HONDT, IE DESMOULINS, J MOURATO-RIBEIRO, A-L MARTIN, J-S FRENEL Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France JAMA Netw Open. 2022 Sep1 ;5(9) I. F : 13.353 Sigaps : A k

15. KFIZAZI, M RETZ, D P PETRYLAK, J C GOH, J PEREZ-GRACIA, L LACOMBE, S ZSCHÄBITZ, M BUROTTI, **H MAHAMMEDI**, G GRAVIS, D ASSE BASTOS, S L MCCUNE, J C VAZQUEZ LIMON, E M KWAN, D CASTELLANO, A FLECHON, F SAAD, M-O GRIMM, D R SHAFFER, A J ARMSTRONG, P BHAGAVATHEESWARAN, N P AMIN, K ÜNSAL-KAÇMAZ, X WANG, J LI, A LOEHR, R K PACHYNSKI Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial J Immunother Cancer. 2022 Aug ;10(8) :e004761 I.F : 12.469 Sigaps : A k

16. V EIFERMAN, G LE GUENNO, N BOIRET-DUPRE, **B BARRES**, L LUCIANI, P E FOURNIER Atypical Borrelia garinii infection in an immunocompromised patient mimicking high-grade lymphoma Inf J Infect Dis. 2022 Aug ;12 :102-104 I.F : 12.074 Sigaps : B k

17. S S BADVE, **F PENAULT-LLORCA**, J S REIS-FILHO, R DEURLOO, K P SIZIOPIKOU, C D'ARRIGO, G VIALE Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130 J Natl Cancer Inst. 2022 May 9 ;114(5) :664-675 I.F : 11.816 Sigaps : B 2

18. P-Y LE ROUX, P-B BONNEFOY, A BAHLOUL, B DENIZOT, B BARRES, C MOREAU-TRIBY, A GIRMA, A PALLARDY, Q CEYRAT, L SARDA-MANTEL, M RAZZOUK-CADET, R ZSIGMOND, **F CACHIN**, G KARCHER, P-Y SALAUN Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: A Multicenter Study J Nucl Med. 2022 Jul ;63(7) :1070-1074 I. F : 11.082 Sigaps : A k

19. H OTMAN, J FARCE, P MENERET, X PALARD-NOVELLO, P-J LE RESTE, I LECOULLARD, E VAULEON, M CHANCHOU, B CARSIN NICOL, M BERTAUX, A DEVILLERS, D MARIANO-GOULART, **F CACHIN**, A GIRARD, F LE JEUNE Delayed [18 F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis Clin Nucl Med. 2022 Sep 1 ;47(9) :800-806 I.F : 10.782 Sigaps : A k

- 20.** P-B BONNEFOY, A BAHLOUL, B DENIZOT, B BARRES, C MOREAU-TRIBY, A GIRMA, A PALLARDY, Q CEYRA, L SARDA-MANTEL, M RAZZOUK-CADET, R ZSIGMOND, **F CACHIN**, G KARCHER, P-Y SALAUN, P-Y LE ROUX Functional Alterations Due to COVID-19 Lung Lesions-Lessons From a Multicenter V/Q Scan-Based Registry Clin Nucl Med. 2022 Aug 1 ;47(8) :e540-e547 I.F : 10.782 Sigaps : A k
- 21.** A LETANG, A CROMBE, C ROUSSEAU, P SARGOS, **C MERLIN**, C CANTAREL, A-L CAZEAU Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence Clin Nucl. Med. 2022 Aug 1 ;47(8) :e529-e539 I.F : 10.782 Sigaps : A k
- 22.** **E MAIRAL**, E CHEVALIER, L IMBERT, C BOURSIER-JOPPIN, A VERGER Multiparametric 18F-FDG and 68GA-DOTATOC PET Imaging in Bone Metastatic Meningioma Before Radionuclide Therapy: Assessment of Tumor Heterogeneity Clin Nucl Med. 2022 Mar 1 ;47(3) :e321-e322 I.F : 10.782 Sigaps : A 1
- 23.** C FELDMAN, C L SPRUNG, S D MENTZELOPOULOS, A POHRT, C HARTOG, C DANBURY, M WEISS, A AVIDAN, A ESTELLA, G M JOYNT, **A LAUTRETTE**, E GEAT, G ÉLO, E SØREIDE, O LESIEUR, M G BOCCI, S MULLICK, A ROBERTSEN, R SREEDHARAN, H-H BÜLOW, P A MAIA, M CRUZ MARTIN-DELGADO, J F COSGROVE, N BLACKWELL, S PEREZ-PROTTO, G A RICHARDS; ETHICUS-2 STUDY GROUP Global Comparison of Communication of End-of-Life Decisions in the ICU Chest. 2022 Nov ;162(5) :1074-1085 I.F : 10.262 Sigaps : A k
- 24.** **E MAIRAL**, L IMBERT, P-Y MARIE, A BAHLOUL Three-phase bone quantitative-SPECT of navicular bones with a high-sensitivity whole-body CZT-camera in a Müller-Weiss syndrome Eur J Nucl Med Mol Imaging. 2022 Jul ;49(9) :3295-3296 I.F : 10.057 Sigaps : A 1
- 25.** G HOUVENAEGHEL, A DE NONNEVILLE, M COHEN, J-M CLASSE, F REYAL, C MAZOUNI, C FAURE, A MARTINEZ, M-P CHAUVET, E DARAI, C COUTANT, P-E COLOMBO, **P GIMBERGUES**, A-S AZUAR, R ROUZIER, C TUNON DE LARA, P CROCHET, S RUA, A GONÇALVES Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study Eur J Cancer. 2022 Nov ;176 :58-69 I.F : 10.002 Sigaps : B k
- 26.** X BAEZ-NAVARRO, R SALGADO, C DENKERT, J K LENNERZ, **F PENAULT-LLORCA**, G VIALE, J M S BARTLETT, C H M VAN DEURZEN Selecting patients with HER2-low breast cancer: Getting out of the tangle Eur J Cancer. 2022 Nov ;175 :187-192 I.F : 10.002 Sigaps : B k
- 27.** S DELALOGUE, S DUREAU, V D'HONDT, I DESMOULINS, P-E HEUDEL, F P DUHOUX, C LEVY, F LEREBOURS, **M A MOURET-REYNIER**, F DALENC, J-S FRENEL, C JOUANNAUD, L VENAT-BOUVET, S NGUYEN, C CALLENS, D GENTIEN, A RAPINAT, H MANDUZIO, A VINCENT-SALOMON, J LEMONNIER, P COTTU; FRENCH BREAST CANCER INTERGROUP UNICANCER-UCBG Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Eur J Cancer. 2022 May ;166 :300-308 I.F : 10.002 Sigaps : B k

28. S BALDACCI, B BESSE, V AVRILLON, B MENNECIER, J MAZIERES, **P DUBRAY-LONGERAS**, A B CORTOT, R DESCOURT, H DOUBRE, X QUANTIN, M DURUISSEAU, I MONNET, D MORO-SIBILOT, J CADRANEL, C CLEMENT-DUCHENE, S COUSIN, CHARLES RICORDEL, P MERLE, J OTTO, S SCHNEIDER, A LANGLAIS, F MORIN, V WESTEEL, N GIRARD Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort Eur J Cancer. 2022 May ;166 :51-59
I.F : 10.002 Sigaps : B k

29. F DALENC, A LUSQUE, T DE LA MOTTE ROUGE, B PISTILLI, E BRAIN, D PASQUIER, M DEBLED, J-C THERY, A GONÇALVES, I DESMOULINS, C LEVY, L UWER, J-M FERRERO, J-C EYMARD, **M-A MOURET-REYNIER**, A PATSOURIS, J-S FRENEL, T PETIT , M CHEVROT, T BACHELOT, S GUIU Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Eur J Cancer. 2022 JMar ;164 :70-79
I.F : 10.002 Sigaps : B k

30. B ACS, S C Y LEUNG, K M KIDWELL, I ARUN, R AUGULIS, S S BADVE, Y BAI, A L BANE, J M S BARTLETT, J BAYANI, G BIGRAS, A BLANK, H BUIKEMA, M C CHANG, R L DIETZ, A DODSON, S FINEBERG, C M FOCKE, D GAO, A M GOWN, C GUTIERREZ, J HARTMAN, Z KOS, A-V LÆNKHOLM, A LAURINAVICIUS, R M LEVENSON, R MAHBOUBI-ARDAKANI, M G MASTROPASQUA, S NOFECH-MOZES, C KENT OSBORNE, **F PENAULT-LLORCA**, T PIPER, M A QUINTAYO, T T RAU, S REINHARD, S ROBERTSON, R SALGADO, T SUGIE, B VAN DER VEGT, G VIALE, L A ZABAGLO, D F HAYES, M DOWSETT, T O NIELSEN, D L RIMM; INTERNATIONAL KI67 IN BREAST CANCER WORKING GROUP OF THE BREAST INTERNATIONAL GROUP AND NORTH AMERICAN BREAST CANCER GROUP (BIG-NABCG) Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study Mod Pathol. 2022 Oct ;35(10) :1362-1369
I.F : 8.209 Sigaps : A k

31. M JARY, W-W LIU, D YAN, I BAI, A MURANYI, E COLLE, I BROCHERIOU, A TURPIN, **N RADOSEVIC-ROBIN**, P BOURGOIN, F PENAULT-LLORCA, R COHEN, D VERNEREY, T ANDRE, C BORG, K SHANMUGAM, M SVRCEK The Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study Mol Oncol. 2022 Jun ;16(11) :2260-2273
I.F : 7.449 Sigaps : B k

32. A MAILLIEZ, V D'HONDT, A LUSQUE, O CARON, L CABEL, A GONCALVES, M DEBLED, L GLADIEFF, J-M FERRERO, T PETIT, **M A MOURET-REYNIER**, J-C EYMARD, C LEVY, L UWER, M LEHEURTEUR, I DESMOULINS, T BACHELOT, J-S FRENEL, T DE LA MOTTE ROUGE, G SIMON, W JACOT, S DELALOGUE Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database Int J Cancer. 2022 Sep 26. 10.1002
I.F : 7.316 Sigaps : B k

33. P BOUDOU-ROUQUETTE, E MARTIN, E KEMPF, N PENEL, M TOULMONDE, E BOMPAS, F DUFFAUD, N FIRMIN, F BERTUCCI, J-E KURTZ, L CHAIGNEAU, N ISAMBERT, E SAADA-BOUZID, **P DUBRAY-LONGERAS**, F LAROUSSERIE, P ANRACT, C CHEVREAU, J-Y BLAY, S PIPERNO-NEUMANN; GSF-GETO, RESOS AND NETSARC+ Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group Int J Cancer. 2022 Mar 1 ;150(5) :825-836
I.F : 7.316 Sigaps : B k

34. F VERDONK, D FEYAERTS, R BADENES, J A BASTARACHE, A BOUGLE, W ELY, B GAUDILLIERE, C HOWARD, K KOTFIS, **A LAUTRETTE**, M LE DORZE, B JOSEPH MANKIDY, M A MATTHAY, C K MORGAN, A MAZERAUD, B V PATEL, R PATTNAIK, J REUTER, M J SCHULTZ, T SHARSHAR, G S SHRESTHA, C VERDONK, L B WARE, R PIRRACCHIO, M JABAUDON Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience Anesth Crit Care Pain Med. 2022 Oct ;41(5) :101121
I.F : 7.025 Sigaps : B k

- 35.** C MIRJOLET, I DIALLO, A BERTAUT, C VERES, P SARGOS, S HELFRE, M-P SUNYACH, G TRUC, C LE PECHOUX, A PAUMIER, A DUCASSOU, M JOLNEROVSKI, J THARIAT, **M LAPEYRE**, A CORDOBA, M-MAHE, P MAINGON Treatment related factors associated with the risk of breast radio-induced-sarcoma Radiother Oncol. 2022 Jul ;171 :14-21 I.F : 6.901 Sigaps : B k
- 36.** **J BIAU**, C NUTTING, J A LANGENDIJK, T FREDERIC-MOREAU, J THARIAT, L PIRAM, R BELLINI, N SAROUL, N PHAM DANG, B O'SULLIVAN, J GIRALT, P BLANCHARD, J BOURHIS, M LAPEYRE Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers Radiother Oncol. 2022 May ;170 :48-54 I.F : 6.901 Sigaps : B 1
- 37.** A MERLOTTI, D ALTERIO, E ORLANDI, S RACADOT, P BONOMO, P FRANCO, E D'ANGELO, S URSINO, Y POINTREAU, **M LAPEYRE**, P GRAFF, A DI RITO, A ARGENONE, D MUSIO, F DE FELICE, F DIONISI, G FANETTI, I D'ONOFRIO, L BELGIOIA, M MADDALO, M SCRICCILOLO, J BOURHIS, E RUSSI, J THARIAT AIRO GORTEC consensus on postoperative radiotherapy (PORT) in low-intermediate risk early stages oral squamous cell cancers (OSCC) Radiother Oncol. 2022 Dec ;1777 :95-104 I.F : 6.901 Sigaps : B k
- 38.** D PRESTI, J HAVAS, D SOLDATO, P LAPIDARI, E MARTIN, B PISTILLI, C JOUANNAUD, G EMILE, O RIGAL, M FOURNIER, P SOULIE, **M-A MOURET-REYNIER**, C TARPIN, M CAMPONE, S GUILLERMET, A-L MARTIN, S EVERHARD, A DI MEGLIO Factors associated with enrolment in clinical trials among women with early-stage breast cancer ESMO Open. 2022 Jun ;7(3) :100513 I.F : 6.883 Sigaps : B k
- 39.** C MOREAU-BACHELARD, L CAMPION, M TOULMONDE, A LE CESNE, M BRAHMI, A ITALIANO, O MIR, S PIPERNO-NEUMANN, V LAURENCE, N FIRMIN, N PENEL, F DUFFAUD, C CHEVREAU, F BERTUCCI, B NARCISO, **P DUBRAY-LONGERAS**, C DELCAMBRE, E SAADA-BOUZID, P BOUDOU-ROUQUETTE, P SOULIE, C PERRIN, J Y BLAY, E BOMPAS Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) ESMO Open. 2022 Apr ;7(2) :100402 I.F : 6.883 Sigaps : B k
- 40.** A BEDDOK, V CALUGARU, L DE MARZI, P GRAFF, J-L DUMAS, F GOUDJIL, R DENDALE, M MINSAT, **P VERRELLE**, I BUVAT, G CREHANGE Clinical and technical challenges of cancer reirradiation: Words of wisdom Crit Rev Oncol Hematol. 2022 Jun ;174 :103655 I.F : 6.625 Sigaps : B k
- 41.** M BINI, S QUESADA, P MEEUS, M RODRIGUES, E LEBLANC, A FLOQUET, P PAUTIER, F MARCHAL, M PROVANSAL, L CAMPION, S CAUSERET, S GOURGOU, I RAY-COQUARD, J-M CLASSE, **C POMEL**, T DE LA MOTTE ROUGE, E BARRANGER, A M SAVOYE, C GUILLEMET, L GLADIEFF, M DEMARCHI, R ROUZIER, C COURTINARD, C ROMEO, F JOLY Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database Cancers (Basel). 2022 Aug 21 ;14(16) :4040 I.F : 6.575 Sigaps : B k
- 42.** P PUJOL, K YAUY, A COFFY, N DUFORET-FREBOURG, S GABTENI, J-P DAURES, **F PENAULT LLORCA**, F THOMAS, K HUGHES, C TURNBULL, V GALIBERT, C RIDEAU, C CORSINI, L COLLET, B YOU, D GENEVIEVE, N PHILIPPE Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation Cancers (Basel). 2022 Jul 4 ;14(13) :3266 I.F : 6.575 Sigaps : B k

2. Publications

- 43.** Y FAYET, C CHEVREAU, G DECANter, C DALBAN, P MEEUS, S CARRERE, L HADDAG-MILIANI, F LE LOARER, S CAUSERET, D ORBACH, M KIND, L-R LE NAIL, G FERRON, H LABROSSE, L CHAIGNEAU, F BERTUCCI, J-C RUZIC, V LE BRUN LY, F FARSI, E BOMPAS, S NOAL, A VOZY, A DUCOULOMBIER, C BONNET, S CHABAUD, F DUCIMETIERE, C TLEMSANI, M ROPARS, O COLLARD, P MICHELIN, J GANTZER, **P DUBRAY-LONGERAS**, M RIOS, P SOIBINET, A LE CESNE, F DUFFAUD, M KARANIAN, F GOUIN, R TETREAU, C HONORE, J-M COINDRE, I RAY-COQUARD, S BONVALOT, J-Y BLAY No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome? *Cancers (Basel)*. 2022 May 25 ;14(11) :2620 I.F : 6.575 Sigaps : B k
- 44.** N FERRAND, A FERT, R MORICHON, **N RADOSEVIC-ROBIN**, M ZAOUI, M SABBAAHWISP₂/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells *Cancers (Basel)*. 2022 Mar 14 ;14(6) :1487 I.F : 6.575 Sigaps : B k
- 45.** A DE BERNARDI, A DUFRESNE, **F MISHPELLANY**, J-Y BLAY, I RAY-COQUARD, M BRAHMI Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond *Cancers (Basel)*. 2022 Feb 20 ;14(4) :1064 I.F : 6.575 Sigaps : B 3
- 46.** L COLLET, J PERON, **F PENAULT-LLORCA**, P PUJOL, J LOPEZ, G FREYER, B YOUPARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers *Cancers (Basel)*. 2022 Jan 25 ;14(3) :599 I.F : 6.575 Sigaps : B 3
- 47.** C ROMEO, O LE SAUX, M JACOBS, F JOLY, G FERRON, L FAVIER, J-D FUMET, N ISAMBERT, P-E COLOMBO, R SABATIER, L BASTIDE, A CHARRETON, M DEVOUASSOUX-SHISHEBORAN, W GERTYCH, C DUBOT, D BELLO ROUFAL, G BATAILLON, D BERTON, E KALBACHER, P PAUTIER, **C POMEL, C CORNOU**, I TREILLEUX, A LARDY-CLEAUD, I RAY-COQUARD Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network *Cancers (Basel)*. 2022 Jan 12 ;14(2) :354 I.F : 6.575 Sigaps : B k
- 48.** E FAUGERAS, L VERONESE, G JEANNIN, H JANICOT, S BAILLY, J-O BAY, B PEREIRA, A CAYRE, **F PENAULT-LLORCA, F CACHIN**, P MERLE, A TCHIRKOV Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker *Cancers (Basel)*. 2022 Dec 31 ;15(1) :290 I.F : 6.575 Sigaps : B k
- 49.** L SILINA, F DUFOUR, A RAPINAT, C REYES, D GENTIEN, F MAKSUT, F RADVANYI, **P VERRELLE**, I BERNARD-PIERROT, F MEGNIN-CHANET Tyro₃ Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation *Int J Mol Sci*. 2022 Aug 4 ;23(15) :8671 I.F : 6.208 Sigaps : B k
- 50.** E LE BOITEUX, P-O GUICHET, K MASLIANTSEV, B MONTIBUS, C VAURS-BARRIERE, C GONTHIER-GUERET, E CHAUTARD, **P VERRELLE**, L KARAYAN-TAPON, A FOGLI, F COURT, P ARNAUD The Long Non-Coding RNA HOXA-AS₂ Promotes Proliferation of Glioma Stem Cells and Modulates Their Inflammation Pathway Mainly through Post-Transcriptional Regulation *Int J Mol Sci*. 2022 Apr 25 ;23(9) :4743 I.F : 6.208 Sigaps : B k
- 51.** C MENNETREY, M LE BRAS, A BANDO-DELAUNAY, L AL-MANSOUR, M HAISSAGUERRE, M BATISSE-LIGNIER, E OUVRARD, C ANSQUER, T WALTER, L DE MESTIER, **A KELLY**, G TLILI, S GIRAUD, M-O NORTH, M-F ODOU, B GOICHOT, T CUNY, ANDERSON LOUNDOU, P ROMANET, A IMPERIALE, D TAÏEB Value of Somatostatin Receptor PET/CT in Patients With MEN₁ at Various Stages of Their Disease *J Clin Endocrinol Metab*. 2022 Apr 19 ;107(5) :e205-e2064 I.F : 6.134 Sigaps : B k

52. S GAILLARD, S ADENIRAN, C VILLA, A JOUINOT, M-L RAFFIN-SANSON, L FEUVRET, **P VERRELLE**, F BONNET, A DOHAN, J BERTHERAT, G ASSIE, B BAUSSART Outcome of giant pituitary tumors requiring surgery Front Endocrinol (Lausanne). 2022 Aug 29 ;13 :975560 I.F : 6.055 Sigaps : B k

53. A JOSEPH, M ELOIT, E AZOULAY, G KAPLANSKI, F PROVOT, C PRESNE, A WYNCKEL, S GRANGE, É RONDEAU, F PENE, Y DELMAS, **A LAUTRETTE**, C BARBET, C MOUSSON, J-P COINDRE, P PEREZ, M JAMME, J-F AUGUSTO, P POUILLIN, F JACOBS, K EL KAROUI, C VIGNEAU, M ULRICH, T KANOUNI, M LE QUINTREC, M HAMIDOU, S VILLE, A CHARVET-RUMPLER, M OJEDA-URIBE, P GODMER, V FREMEAUX-BACCHI, A VEYRADIER, J-M HALIMI, P COPPO Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure Res Pract Thromb Haemost. 2022 May 18 ;6(4) I.F : 5.953 Sigaps : B k

54. **E JOUBERTON**, A VOISSIERE, **F PENNAULT-LLORCA**, **F CACHIN**, E MIOT-NOIRAUT Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs Am J Cancer Res. 2022 Mar 15 ;12(3) :1116-1128 I.F : 5.942 Sigaps : C 3

55. N SAROUL, M PUECHMAILLE, C LAMBERT, A SAYED HASSAN, **J BIAU**, **M LAPEYRE**, T MOM, **M BERNADACH**, L GILAIN Prognosis in Head and Neck Cancer : Importance of Nutritional and Biological Inflammatory Status Otolaryngol Head Surg. 2022 Jan ;166(1) :118-127 I.F : 5.591 Sigaps : A ADA

56. L BEAL, V NAVEL, B PEREIRA, **F MAGNIER**, S L WATSON, J S BAKER, F CHIAMBARETTA, F DUTHEIL Efficacy of Thin and Ultrathin Descemet Stripping Automated Endothelial Keratoplasty and Influence of Graft Thickness on Postoperative Outcomes: Systematic Review and Meta-analysis Am J Ophtalmol. 2022 Aug ;240 :170-186 I.F : 5.488 Sigaps : B k

57. M CARAUSU, M CARTON, L CABEL, A PATSOURIS, C LEVY, B VERRET, D PASQUIER, M DEBLED, ANTHONY GONÇALVES, I DESMOULINS, I LECOULLARD, T BACHELOT, J-M FERRERO, J-C EYMARD, **M-A MOURET-REYNIER**, M CHEVROT, E DE MAIO, L UWER, J-S FRENEL, M LEHEURTEUR, T PETIT, A DARLIX, L BOZEC Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database Ther Adv Med Oncol. 2022 Feb 26 ;14 I.F : 5.485 Sigaps : C k

58. A MALLET, A LUSQUE, C LEVY, B PISTILLI, E BRAIN, D PASQUIER, M DEBLED, J C THERY, A GONÇALVES, I DESMOULINS, T DE LA MOTTE ROUGE, C FAURE, J M FERRERO, J C EYMARD, **M A MOURET-REYNIER**, A PATSOURIS, PL COTTU, F DALENC, T PETIT, O PAYEN, L UWER, S GUIU, J S FRENEL Real-world evidence of the management and prognosis of young women (40 years) with de novo metastatic breast cancer Ther Adv Med Oncol. 2022 Jan 21 ;14 I.F : 5.485 Sigaps : C k

59. D MORVAN, **F CACHIN** Untargeted 2D NMR Metabolomics of [¹³C- methyl]Methionine-Labeled Tumor Models Reveals the Non-DNA Methylome and Provides Clues to Methyl Metabolism Shift during Tumor Progression J Proteome Res. 2022 Apr 1 ;21(4) :940-952 I.F : 5.37 Sigaps : B 1

60. S CROCE, M DEVOUASSOUX-SHISHEBORAN, P PAUTIER, I RAY-COQUARD, I TREILLEUX, A NEUVILLE, LARNOULD, P-A JUST, M A LE FRERE BELDA, GAVEROUS, A LEROUX, E MERY, D LOUSSOUARN, N WEINBRECK, S LE GUELLEC, **F MISHPELLANY**, P MORICE, F GUYON, C GENESTIE Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group Gynecol Oncol. 2022 Sep 13 ;S0090-8258(22)00515-7 I.F : 5.304 Sigaps : B k

61. Q DOMINIQUE THOMAS, A BOUSSERE, J-M CLASSE, **C POMEL**, H COSTAZ, M RODRIGUES, I RAY-COQUARD, L GLADIEFF, R ROUZIER, T DE LA MOTTE ROUGE, S GOUY, E BARRANGER, R SABATIER, A FLOQUET, F MARCHAL, C GUILLEMET, V POLIVKA, A-L MARTIN, P-E COLOMBO, F FITENI Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort Gynecol Oncol. 2022 Oct ;167(1) :11-21 I.F : 5.304 Sigaps : B k

62. F JOLY, M FABBRO, D BERTON, J LEQUESNE, A ANOTA, A PUSZKIEL, A FLOQUET, H VEGAS, H BOURGEOIS, L BENGRINE LEFEVRE, B YOU, F POMMERET, A LORTHOLARY, D SPAETH, A-C HARDY-BESSARD, C ABDEDDAIM, M-C KAMINSKY-FORRETT, M TOD, J-E KURTZ, F DEL PIANO, J MEUNIER, N RABAN, J ALEXANDRE, **M-A MOURET-REYNIER**, I RAY-COQUARD, M PROVANSAL GROSS, P-E BRACHET Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study Gynecol Oncol. 2022 Sep ;166(3) :389-396 I.F : 5.304 Sigaps : B k

63. S HENNO, C JEANNE, T DE LA MOTTE ROUGE, C GENESTIE, I TREILLEUX, S CROCE, P A JUST, M A LE FRERE-BELDA, E GUINAUDEAU, **F PENAULT-LLORCA**, L ARNOULD, E MERY-LAMARCHE, A LEROUX, A S LEMAIRE, G AVEROUS, O RENAUD, E CHARAFE-JAUFFRET, C BONNEAU, C LEAHA, I RAY-COQUARD, M DEVOUASSOUX-SHISHEBORAN Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG) Gynecol Oncol. 2022 Jun ;165(3) :637-641 I.F : 5.304 Sigaps : B k

64. P HARTE, **M A MOURET-REYNIER**, S PIGNATA, C CROPET, A GONZALEZ-MARTIN, G BOGNER, K FUJIWARA, I VERGOTE, N COLOMBO, T JAKOBI NØTTRUP, A FLOQUET, A EL-BALAT, G SCAMBIA, E M GUERRA ALIA, M FABBRO, B SCHMALFELDT, A-C HARDY-BESSARD, I RUNNEBAUM, E PUJADE-LAURAIN, I RAY-COQUARD Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Gynecol Oncol. 2022 Feb ;164(2) :254-264 I.F : 5.304 Sigaps : B 2

65. OTREDAN, M PROVANSAL, CABDEDDAIM, ALARDY-CLEAUD, A-C HARDY-BESSARD, E KALBACHER, A FLOQUET, L VENAT-BOUVET, A LORTHOLARY, O POP, J-S FRENEL, M CANCEL, R LARGILLIER, C LOUVET, B YOU, A ZANNETTI, A ANOTA, I TREILLEUX, D PISSALOUX, A HOULIER, A-M SAVOYE, **M-A MOURET-REYNIER**, J MEUNIER, C-BRIAC LEVACHE, F BROCARD, I RAY-COQUARD Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR) Gynecol Oncol. 2022 Jan ;164(1) :18-26 I.F : 5.304 Sigaps : B k

66. M N CHAO, J-M CHEZAL, E DEBITON, D CANITROT, T WITKOWSKI, **S LEVESQUE**, F DEGOUL, S TARRIT, B WENZEL, E MIOT-NOIRALT, A SERRE, A MAISONIAL-BESSET A Convenient Route to New (Radio)Fluorinated and (Radio)Iodinated Cyclic Tyrosine Analogs Pharmaceuticals (Basel). 2022 Jan 28 ;15(2) :162 I.F : 5.215 Sigaps : B k

67. M-E PINSON, F COURT, A MASSON, Y RENAUD, A FANTINI, O BACOEUR-OUZILLOU, M BARRIERE, B PEREIRA, P-O GUICHET, **E CHAUTARD**, L KARAYAN-TAPON, P VERRELLE, P ARNAUD, C VAURS-BARRIERE L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus Hum Mol Genet. 2022 Aug 17 ;31(15) :2606-2622 I.F : 5.121 Sigaps : B k

- 68.** **G GALVAING**, N D'OSTREVVY, L FILAIRE, M FARHAT Resection of a Large Lipoma Invading the Right Atrium Ann Thorac Surg. 2022 Mar. 113(3) I.F : 5.102 Sigaps : B 1
- 69.** M CASILE, **J PASSILDAS**, B VIRE, **I MOLNAR**, **X DURANDO** hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study Front Neurol. 2023 Jan 11 ;13 :1073476 I.F : 4.086 Sigaps : C DA
- 70.** **E THIVAT**, M CHANCHOU, S MATHIEU, S LEVESQUE, T BILLOUX, P AUZELOUX, N SAS, I MOLNAR, E JOUBERTON, J ROUANET, G FOIS, L MAIGNE, M-J GALMIER, F PENAULT-LLORCA, E MIOT-NOIRAUULT, X DURANDO, F CACHIN Assessment of 99mTc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT) Front Med (Lausanne). 2022 Oct 12 ;9 :993151 I.F : 5.058 Sigaps : C 1
- 71.** H VEYSSIERE, Y BIDET, F PENAULT-LLORCA, N RADOSEVIC-ROBIN, **X DURANDO** Circulating proteins as predictive and prognostic biomarkers in breast cancer Clin Proteomics. 2022 Jul 11 ;19(1) :25 I.F : 5 Sigaps : B 5
- 72.** A BRIAT, C JACQUES, M MALIGE, L SUDRE, G NOURISSAT, P AUZELOUX, H GUEHRING, **F CACHIN**, F BERENBAUM, E MIOT-NOIRAUULT 99mTc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model Sci Rep. 2022 May 17 ;12(1) :8146 I.F : 4.996 Sigaps : C k
- 73.** A MAISONIAL-BESSET, T WITKOWSKI, M QUINTANA, S BESSE, V GAUMET, A CORDONNIER, C ALLIOT, A VIDAL, C DENEVAULT-SABOURIN, S TARRIT, **S LEVESQUE**, E MIOT-NOIRAUULT, J-M CHEZAL Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the 64Cu- Labelling of Immunoconjugates Molecules. 2022 DEC 22.28(1) :75 I.F : 4.927 Sigaps : C k
- 74.** J PORTE, C SAINT-MARTIN, T FREDERIC-MOREAU, M-A MASSIANI, L BOZEC, K CAO, **P VERRELLE**, J OTZ, E JADAUD, M MINSAT, A LANGER, N GIRARD, G CREHANGE, A BEDDOK Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases Biomedicines. 2022 Sep 10 ;10(9) :2249 I.F : 4.757 Sigaps : C k
- 75.** B LEYRAT, T KHALILL, J-J LEMAIRE, M CASILE, **I MOLNAR**, **V DEDIEU**, V CHASSIN, G DUPIC, **A BELLIERE**, **X DURANDO**, **M LAPEYRE**, P VERRELLE, **J BIAU** Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors Clin Transl Radiat Oncol. 2022 Jun 1 ;36 :1-8 I.F : 4.739 Sigaps : C DA
- 76.** G HOUVENAEGHEL, A DE NONNEVILLE, N CHOPIN, J-M CLASSE, C MAZOUNI, M-P CHAUVET, F REYAL, C TUNON DE LARA, E JOUVE, R ROUZIER, E DARAÏ, **P GIMBERGUES**, C COUTANT, A S AZUAR, R VILLET, P CROCHET, S RUA, M BANNIER, MONIQUE COHEN, J-M BOHER The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases Cancer Med. 2022 Sep 20. I.F : 4.711 Sigaps : C k

77. M SEBAI, D TULASNE, S M CAPUTO, V VERKARRE, M FERNANDES, C GUERIN, F REINHART, S ADAMS, C MAUGARD, O CARON, M GUILLAUD-BATAILLE, P BERTHET, **Y-J BIGNON**, B BRESSAC-DE PAILLERETS, N BURNICHON, J CHIESA, S GIRAUD, S LEJEUNE, J-M LIMACHER, A DE PAUW, D STOPPALYONNET, H ZATTARA-CANNONI, S DEVEAUX, R LIDEREAU, S RICHARD, E ROULEAU Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I Hum Mutat. 2022 Mar ;43(3) :316-327 I.F : 4.7 Sigaps : C k

78. FGOUIN, ESTOECKLE, CHONORE, M ROPARS, M JAFARI, J C MATTEI, A ROCHWERGER, S CARRERE, D WAAST, G FERRON, J C MACHIAVELLO, P ANRACT, F MARCHAL, F SIRVEAUX, O MARCO, J GUIRAMAND, B PAQUETTE, A DI MARCO, S CAUSERET, J-M GUILLOIT, P SOIBINET, D TZANIS, **P GIMBERGUES**, F FIORENZA, F DUJARDIN, L R LE NAIL, J-C RUZIC, C CHEMIN-AIRIAU, M MORELLE, P MEEUS, M KARANIAN, F LE LOARER, G VAZ, J-Y BLAY; NETSARC/RREPS and French Sarcoma Group-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) networks Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis BMC Cancer. 2022 Oct 3 ;22(1) :1034 I.F : 4.638 Sigaps : C k

79. J C H YANG, MARCIA S BROSE, GILBERTO CASTRO, EDWARD S KIM, ULRIK N LASSEN, S LEYVRAZ, A PAPPO, F LOPEZ-RIOS, J A REEVES, M FELLOUS, **F PENAULT-LLORCA**, E R RUDZINSKI, G TABATABAI, G VASSAL, A DRILON, J TRENT Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib BMC Cancer. 2022 Jun 7 ;22(1) :625 I.F : 4.638 Sigaps : C k

80. E THIVAT, J ROUANET, P AUZELOUX, **N SAS**, E JOUBERTON, S LEVESQUE, T BILLOUX, S MANSARD, I MOLNAR, M CHANCHOU, G FOIS, L MAIGNE, J-M CHEZAL, E MIOT-NOIRAUT, M D'INCAN, **X DURANDO**, **F CACHIN** Phase I study of [¹³¹I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol BMC Cancer. 2022 Apr 25 ;22(1) :417 I.F : 4.638 Sigaps : C 1

81. N HANH TO, H QUY NGUYEN, A THIOLAT, B LIU, J COHEN, **N RADOSEVIC-ROBIN**, Y BELKACEMI; TRANSATLANTIC RADIATION ONCOLOGY NETWORK (TRONE) & ASSOCIATION OF RADIOTHERAPY, AND ONCOLOGY OF THE MEDITERRANEAN AREA (AROME) Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review Breast Cancer Res Treat 2022 Jun ;193(2) :265-279 I.F : 4.624 Sigaps : C ADA

82. M BRINGUIER, M CARTON, C LEVY, A PATSOURIS, D PASQUIER, M DEBLED, O RIGAL, W JACOT, A GONÇALVES, I DESMOULINS, T DE LA MOTTE ROUGE, T BACHELOT, J-M FERRERO, J-C EYMARD, M UNG, **M-A MOURET-REYNIER**, T PETIT, M CHEVROT, L UWER 19, C COURTINARD, J-S FRENEL, A VIANZONE, C BALDINI Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort Breast Cancer Res Treat. 2022 Feb ;191(3) :577-587 I.F : 4.624 Sigaps : C k

83. P CORBAUX, A LARDY-CLEAUD, M ALEXANDRE, M FONTANILLES, C LEVY, A ADRIANO VIANSONE, A MAILLIEZ, M DEBLED, A GONCALVES, F LE DU, F LEREBOURS, J-M FERRERO, J-C EYMARD, **M-A MOURET-REYNIER**, T PETIT, J-S FRENEL, F DALENC, C COURTINARD, M CHAIX, T BACHELOT Breast Cancer Res Treat. 2022 Jan ;191(1) :191-207 I.F : 4.624 Sigaps : C k

- 84.** M BAILLY, L PELISSIER, E COUDEYRE, B EVRARD, R BINGULA, C ROCHETTE, L MERIADE, C BLAVIGNAC, A-C FOURNIER, **Y-J BIGNON**, F RANNOU, F DUTHEIL, D THIVEL, M DUCLOS Systematic Review of COVID-19-Related Physical Activity-Based Rehabilitations: Benefits to Be Confirmed by More Robust Methodological Approaches *Int J Environ Res Public Health*. 2022 Jul 25 ;19(15) :9025
I.F : 4.614 Sigaps : B k
- 85.** **F PENAULT-LLORCA**, K M KERR, P GARRIDO, E THUNNISSEN, E DEQUEKER, N NORMANNO, S J PATTON, J FAIRLEY, J KAPP, D DE RIDDER, A RYSKA, H MOCH Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment *Virchows Arch*. 2022 Sep ;481(3) :351-366
I.F : 4.535 Sigaps : C 1
- 86.** **F PENAULT-LLORCA**, K M KERR, P GARRIDO, E THUNNISSEN, E DEQUEKER, N NORMANNO, S J PATTON, J FAIRLEY, J KAPP, D DE RIDDER, A RYSKA, H MOCH Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management *Vichows Arch*. 2022 Sep ;481(3) :335-350
I.F : 4.535 Sigaps : C 1
- 87.** S MOTTON, K VERGRIETE, L NGUYEN VANPHI, E LAMBAUDIE, A BERTHOUMIEU, J POUS, M DELANNES, J PISCIONE, **C CORNOU**, B BATAILLE, D SAXOD, F PILLARD Evaluation of the impact of the COVID-19 lockdown on the quality of life of patients monitored for cancer who practice an adapted physical activity: rugby for health *J Cancer Res Clin Oncol*. 2022 Feb ;148(2) :425-439
I.F : 4.322 Sigaps : C k
- 88.** D SCHNELL, A BOURMAUD, M REYNAUD, S ROULEAU, H MERDJI, A BOIVIN, M BENYAMINA, F VINCENT, **A LAUTRETTE**, C LEROY, Y COHEN, M LEGRAND, J MOREL, J TERREAUX, M DARMON Performance of renal Doppler to predict the occurrence of acute kidney injury in patients without acute kidney injury at admission *J Crit Care*. 2022 Jun ;69 :153983
I.F : 4.298 Sigaps : C k
- 89.** J C HAAN, R BHASKARAN, A ELLAPPALAYAM, Y BIJL, C J GRIFFIOEN, E LUJINOVIC, W M AUDEH, **F PENAULT-LLORCA**, L MITTEMPERGER, A M GLAS MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients *Genes Chromosomes Cancer*. 2022 Mar ;61(3) :148-160
I.F : 4.263 Sigaps : C k
- 90.** A VASSEUR, M CARTON, S GUIU, P AUGEREAU, L UWER, **M-A MOURET-REYNIER**, C LEVY, J-C EYMARD, J-M FERRERO, M LEHEURTEUR, A GONCALVES, M ROBERT, T DE LA MOTTE ROUGE, T BACHELOT, T PETIT, M DEBLED, T GRINDA, I DESMOULINS, L VANLEMMENS, V NICOLAÏ, G SIMON, L CABEL Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study *Breast*. 2022 Oct ;65 :136-144
I.F : 4.254 Sigaps : B k
- 91.** **F MOINARD-BUTOT**, C SAINT-MARTIN, C PFLUMIO, M CARTON, W JACOT, P-H COTTU, V DIERAS, F DALENC, A GONCALVES, M DEBLED, A PATSOURIS, **M-A MOURET-REYNIER**, L VANLEMMENS, M LEHEURTEUR, G EMILE, J-M FERRERO, I DESMOULINS, L UWER, J-C EYMARD, B CHEAIB, C COURTINARD, T BACHELOT, M CHEVROT, T PETIT Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort *Breast*. 2022 Jun ;63 :54-60
I.F : 4.254 Sigaps : B k

92. J BENBENISHTY, F DEKEYSER GANZ, M H ANSTEY, F J BARBOSA-CAMACHO, M G BOCCI, E AYSE ÇIZMECI, K DYBWIK, C INGELS, **A LAUTRETTE**, R C MIRANDA-ACKERMAN, B ESTEBANEZ-MONTIEL, C PLOWRIGHT, B RICOU, A ROBERTSEN, C L SPRUNG We need to better recognise and value the contribution of nurses to end-of-life care (Bloomer, ICCN 2022) Intensive Crit Care Nurs. 2022 Jun ;70 :103225
I.F : 4.235 Sigaps : A k

93. J BENBENISHTY, F DEKEYSER GANZ, M H ANSTEY, F J BARBOSA-CAMACHO, M GR BOCCI, E AYSE ÇIZMECI, K DYBWIK, C INGELS, **A LAUTRETTE**, R C MIRANDA-ACKERMAN, B ESTEBANEZ-MONTIEL, C PLOWRIGHT, B RICOU, A ROBERTSEN, C L SPRUNG Changes in intensive care unit nurse involvement in end of life decision making between 1999 and 2016: Descriptive comparative study Intensive Crit Care Nurs. 2022 Feb ;68 :103138
I.F : 4.235 Sigaps : A k

94. A FLAUS, V HABOUZIT, N DE LEIRIS, J-P VUILLEZ, M-T LECCIA, M SIMONSON, J-L PERROT, **F CACHIN**, N PREVOT Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment Diagnostics (Basel). 2022 Feb 2 ;12(2) :388
I.F : 3.992 Sigaps : C ADA

95. **F MAGNIER**, F DUTHEIL, B PEREIRA, S L WATSON, J S BAKER, F CHIAMBARETTA, V NAVEL Preventive treatment of allograft rejection after endothelial keratoplasty: A systematic review and meta-analysis Acta Ophthalmol. 2022 Aug ;100(5) ;e1061-e1073
I.F : 3.988 Sigaps : C 1

96. A LERE-CHEVALEYRE, **M BERNADACH**, C LAMBERT, L CASSAGNES, M PUECHMAILLE, T MOM, L GILAIN, **M LAPEYRE**, Y BOIRIE, **J BIAU**, N SAROUL Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass Head Neck. 2022 Mar ;44(3) :681-690
I.F : 3.821 Sigaps : B 2

97. R MONGE, C ORIS, M JABAUDON, M BRAÏLOVA, E FUTIER, V SAPIN, B PEREIRA, **A LAUTRETTE** Association between proteinuria trajectories and outcomes in critically ill patients with sepsis or shock PLoS One. 2022 Aug 24 ;17(8) :e0272835
I.F : 3.752 Sigaps : C DA

98. M BAILLY, B EVRARD, E COUDEYRE, C ROCHETTE, L MERIADE, C BLAVIGNAC, A-C FOURNIER, **Y-J BIGNON**, F DUTHEIL, M DUCLOS, D THIVEL Health management of patients with COVID-19: is there a room for hydrotherapeutic approaches? Int J Biometeorol. 2022 May ;66(5) :1031-1038
I.F : 3.738 Sigaps : C k

99. **T HERRMANN**, C MIONE, P-F MONTORIOL, I MOLNAR, A GINZAC, X DURANDO, H MAHAMMEDI Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Oncology. 2022 ;100(2) :114-123
I.F : 3.734 Sigaps : D 1

100. M METZGER, V NAVEL, J-V BARRIERE, **F KWIATKOWSKI**, J HEBRAUD, A MULLIEZ, L BERAL, F CHIAMBARETTA, F DUTHEIL Benefits of using corneal topography to choose subjective refraction technique in keratoconus (RE-CON): a prospective comparative crossover clinical study Graefes Arch Clin Exp Ophthalmol. 2022 Jan ;260(1) :197-207
I.F : 3.535 Sigaps : C k

- 101.** D HORGAN, G CURIGLIANO, O RIEß, P HOFMAN, R BÜTTNER, P CONTE, T CUFER, W M GALLAGHER, N GEORGES, K KERR, **F PENAULT-LLORCA**, K MASTRIS, C PINTO, J VAN MEERBEECK, E MUNZONE, M THOMAS, S UJUPAN, G W VAINER, J-L VELTHAUS, F ANDRE Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe *J Pers Med.* 2022 Jan 8 ;12(1) :72 I.F : 3.508 Sigaps : C k
- 102.** **G GAYRAUD**, D DE CASTRO, K PERRIER, **I MOLNAR**, C DUALE A French nationwide survey on the practice of regional anesthesia for breast cancer surgery *Minervaa Anesthesiol.* 2022 Sep ;88(9) I.F : 3.396 Sigaps : D 1
- 103.** **A SANCHEZ**, **F PENAULT-LLORCA**, **Y-J BIGNON**, L GUY, **D BERNARD-GALLON** Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts *Cancer Genomics Proteomics.* 2022 May-Jun ;19(3) :339-349 I.F : 3.395 Sigaps : D DA
- 104.** Y EL OUADIH, B PEREIRA, J BIAU, B CLAISE, R CHAIX, **P VERRELLE**, T KHALIL, **X DURANDO**, J-J LEMAIRE DTI Abnormalities Related to Glioblastoma: A Prospective Comparative Study with Metastasis and Healthy Subjects *Curr Oncol.* 2022 Apr 16 ;29(4) :2823-2834 I.F : 3.109 Sigaps : D ADA
- 105.** **M KOSSAÏ**, C RADULESCU, J ADAM, A DZIEGIELEWSKI, N SIGNOLLE, M SIBONY, T LEBRET, Y ALLORY, M ROUANNE Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC *Urol Oncol.* 2022 Jan ;40(1) :12 e1-12.e11 I.F : 2.954 Sigaps : D 1
- 106.** H VEYSSIERE, G ALDARAZI, I MOLNAR, **X DURANDO**, **N RADOSEVIC-ROBIN** Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy *Anticancer Res.* 2022 Jul ;42(7) :3583-3594 I.F : 2.435 Sigaps : E DA
- 107.** M COHEN BACRY, A C PHILIPPE, D RIETHMULLER, J L FAUCHERON, **C POMEL** Interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer - retrospective study comparing surgery after 3 cycles or more of chemotherapy *J Gynecol Obstet Hm Reprod.* 2022 Sep ;51(7) :102409 I.F : 2.156 Sigaps : E DA
- 108.** **L FILAIRE**, O MERCIER, A SEGUIN-GIVELET, O TIFFET, P EMMANUEL FALCOZ, P MORDANT, P-Y BRICHON, P LACOSTE, A AUBERT, P THOMAS, F LE PIMPEC-BARTHES, **I MOLNAR**, M VIDAL, **M FILAIRE**, **G GALVAING** Superior vena cava graft infection in thoracic surgery: a retrospective study of the French EPITHOR database *Interact Cardiovasc Thorac Surg.* 2022 Feb 21 ;34(3) :378-185 I.F : 1.978 Sigaps : D DA
- 109.** K ZHOU, J-L RAOUL, A BLANC-LAPIERRE, V SEEGER, M BOISDRON-CELLE, M BOURDON, **H MAHAMMEDI**, A LAMBERT, C MOREAU-BACHELARD, M CAMPONE, T CONROY, **F PENAULT-LLORCA**, M M BELLANGER, F BIGOT COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19) *Clin Med Insights Oncol.* 2022 Apr 18 ;16 I.F : 1.795 Sigaps : E k
- 110.** **F GUILLEMIN**, A-A SERRE, F GASSA, F LORCHEL, M SANDT, F LAFAY, J CHARRET, C RANNOU, P POMMIER Combined intra-cavitary and interstitial image-guided adaptative brachytherapy for cervical stump carcinomas: technical and clinical results of six patients *J Contemp Brachytherapy.* 2022 Jun ;14(3) :248-252 I.F : 1.788 Sigaps : E 1

2. Publications

- 111.** I ZALLE, Y BARTHELEMY, A PIPERATA, **G GALVAING**, L CAMILLERI, N D'OSTREVEY Low fetal age is not a contraindication for extracorporeal membranous oxygenation in COVID-19-related ARDS J Card Surg. 2022 Apr ;17(4) :1059-1062 I.F : 1.778 Sigaps : D k
- 112.** F SELLE, J-J BOFFA, G ETIENNE, A ANGELERGUES, P AUGEREAU, D BERTON, P DIELENSEGER, M FABBRO, C FALANDRY, P FOLLANA, L GLADIEFF, F JOLY, J-E KURTZ, C MATTA, **M-A MOURET-REYNIER**, A SCHMITT, F SCOTTE, C MARJOLLET [Practical management of PARP inhibitors: A French DELPHI consensus] Bull Cancer. 2022 Dec ;109(12) :1245-1261 I.F : 1.318 Sigaps : E k
- 113.** F JOLY, J-M MICHOT, L M DOURTHE, A FLECHON, **H MAHAMMEDI**, D MAILLET, G MOUILLET, D POUESSEL, F ROLLAND, DELPHINE TOPART, L ALBIGES [Metastatic renal cell carcinoma: Management of toxicities of combinations] Bull Cancer. 2022 Jul-Aug ;109(7-8) :844-861 I.F : .318 Sigaps : E k
- 114.** **M LAPEYRE**, S RACADOT, S RENARD, **J BIAU**, **J F MOREIRA**, M C BISTON, Y POINTREAU, J THARIAT, P GRAFF-CAILLEAUD Radiotherapy for oral cavity cancers Cancer Radiother. 2022 Feb-Apr ;26(1-2) :189-198 I.F : 1.217 Sigaps : E 1
- 115.** **J BIAU**, Y POINTREAU, P BLANCHARD, C KHAMPAN, P GIRAUD, **M LAPEYRE**, P MAINGON Radiotherapy for laryngeal cancers Cancer Radiother. 2022 Feb-Apr ;26(1-2) :206-212 I.F : 1.217 Sigaps : E 1
- 116.** Y POINTREAU, **J BIAU**, N DELABY, J THARIAT, **M LAPEYRE** Radiotherapy for hypopharynx cancers Cancer Radiother. 2022 Feb-Apr ;26(1-2) :199-205 I.F : 1.217 Sigaps : E DA
- 117.** P BLANCHARD, **J BIAU**, F HUGUET, S RACADOT, C BERTHOLD, S WONG-HEE-KAM, M-C BISTON, P MAINGON Radiotherapy for nasopharyngeal cancer Cancer Radiother. 2022 Feb-Apr ;26(1-2) :168-173 I.F : 1.217 Sigaps : E 2
- 118.** D ANTONI, L FEUVRET, **J BIAU**, C ROBERT, J-J MAZERON, G NOËL Radiation guidelines for gliomas Cancer Radiother. 2022 Feb-Apr ;26(1-2) :116-128 I.F : 1.217 Sigaps : E 3
- 119.** G DISSAUX, S JOSSET, F THILLAYS, F LUCIA, V BOURBONNE, O PRADIER, D PASQUIER, **J BIAU** Radiotherapy of benign intracranial tumours Cancer Radiother. 2022 Feb-Apr ;26(1-2) :137-146 I.F : 1.217 Sigaps : E DA
- 120.** T LELEU, V BASTIT, M DORE, E KAMMERER, C FLORESCU, M ALFONSI, I TROUSSIER, R-J BENSADOUN, **J BIAU**, E BLAIS, A COUTTE, M DEBERNE, N WIAZZANE, C DUPIN, J-C FAIVRE, P GIRAUD, P GRAFF, S GUIHARD, F HUGUET, G JANORAY, X LIEM, Y POINTREAU, S RACADOT, U SCHICK, S SERVAGI-VERNAT, X S SUN, S THUREAU, J VILLA, N VULQUIN, S WONG 26, V PATRON, J THARIAT Histological mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance Cancer Radiother. 2022 May ;26(3) :440-444 I.F : 1.217 Sigaps : E K
- 121.** A FAVIER, D BOINON, F SALVIAT, C MAZOUNI, B DE KORVIN, C TUNON, A-V SALOMON, I DOUTRIAUX-DUMOULIN, C VAYSSE, F MARCHAL, L BOULANGER, N CHABBERT-BUFFET, S ZILBERMAN, C COUTANT, M ESPIE, M CORTET, **V BOUSSION**, M COHEN, V FERMEUX, C MATHELIN, S MICHIELS, S DELALOGUE, C UZAN, C CHARLES [Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients] Gynecol Obstet Fertil Senol. I.F : 1.058 Sigaps : E k

122. C FALANDRY, F POMMERET, L GLADIEFF, F TINQUAUT, D LORUSSO, **M-A MOURET-REYNIER**, V D'HONDT, D MOLLON-GRANGE, A FLOQUET, S ABADIE-LACOURTOISIE, P-E BRACHET, L STEFANI, F ROUSSEAU, J-S FRENEL, F DEL PIANO, M KOMULAINEN, T WARKUS, O TREDAN, E PUJADE-LAURAINÉ, G FREYER Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study *Lancet Healthy Longev.* 2022 Mar ;3(3) :e176-e185

Sigaps : NC k

123. N HANH TO, **N RADOSEVIC-ROBIN**, Y BELKACEMI Neoadjuvant radiotherapy in triple-negative breast cancer: «the past should not steal the present or hide the future» *Rep Pract Oncol Radiother.* 2022 Mar 22 ;27(1) :180-181

Sigaps : NC 2

124. C LE DEROFF, **L BERGER**, J BELLEC, G BOISSONNAT, H CHESNEAU, S CHIAVASSA, J DESROUSSEAUX, S GEMPP, O HENRY, J JARRIL, D LAZARO, R LEFEUVRE, V PASSAL, F SOLINHAC, C LAFOND, G DELPON Monte Carlo-based software for 3D personalized dose calculations in image-guided radiotherapy *Phys Imaging Radiat Oncol.* 2022 Feb. 26 ;21 :108-114

Sigaps : NC 2

125. C FALANDRY, F POMMERET, L GLADIEFF, F TINQUAUT, D LORUSSO, **M-A MOURET-REYNIER**, V D'HONDT, D MOLLON-GRANGE, A FLOQUET, S ABADIE-LACOURTOISIE, P-E BRACHET, L STEFANI, F ROUSSEAU, J-S FRENEL, F DEL PIANO, M KOMULAINEN, T WARKUS, O TREDAN, E PUJADE-LAURAINÉ, G FREYER Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study *Lancet Healthy Longev.* 2022 Mar ;3(3) :e176-e185

Sigaps : NC k

126. N HANH TO, M KOSSAI, N OUIDIR, N GRELLIER, E ASSAF, I GABELLE-FLANDIN, Y BELKACEMI, **N RADOSEVIC-ROBIN** Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials *Rep Pract Oncol Radiother.* 2022 Dec 29 ;27(6) :1114-1118

Sigaps : NC DA